________
Turbo Cancer Treatment race is on: Johnson & Johnson just completed $2 billion cancer drug buy of Ambrx on March 7, 2024 - Merck, Novartis, Sanofi, Eli Lilly, AbbVie, Pfizer, BMS - they all want in!
Dr. William Makis MD | March 12, 2024
Articles reviewed:
• Mar.11, 2024 - Pfizer bets on cancer drugs to recover from rapid decline of COVID business
• Mar.11, 2024 - Merck Completes Acquisition of Harpoon Therapeutics
• Mar.7, 2024 - Johnson & Johnson Completes Acquisition of Ambrx ($2.0 billion)
• Feb.12, 2024 - AbbVie Completes $10.1 billion Acquisition of ImmunoGen
• Feb.5, 2024 - Novartis in the lead to acquire cancer drug developer MorphoSys-sources
• Dec.26, 2023 - Bristol Myers Squibb announces intent to buy RayzeBio for $4.1 billion (104% premium)
• Nov.22, 2023 - Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
• Oct.8, 2023 - Bristol Myers Squibb announces purchase of Mirati Therapeutics for $5.8 billion
• Oct.3, 2023 - Eli Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
Continuing list of articles reviewed here.
________
The pharmaceutical mafia is continuously creating more sickness:
The latest bullshit mental disorder
The latest bullshit mental disorder
It is going to get a lot worse than any better in the coming years:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.